Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data
Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data作者机构：Department of Pharmacology All India Institute of Medical Sciences
出 版 物：《World Journal of Diabetes》 (世界糖尿病杂志（英文版）（电子版）)
年 卷 期：2014年第5卷第3期
页 面：399-406页
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
主 题：Type 2 diabetes mellitus Sodium-glucose co-transporter 2 Canagliflozin Clinical trial Safety profile
摘 要：Canagliflozin(CFZ) is a member of new class of glucose lowering agents, sodium-glucose co-transporter(SGLT) inhibitors, which got approval by food and drug administration. It has insulin independent action by blocking the transporter protein SGLT2 in the kidneys, resulting in urinary glucose excretion and reduction in blood glucose levels. In clinical trials, CFZ significantly decreased HbA1c level when administered either as monotherapy or as combined therapy with other anti-diabetic drugs. Intriguingly, it showed additional benefits like weight reduction and lowering of blood pressure. The commonly observed side effects were urinary and genital infections. It has exhibited favorable pharmacokinetic and pharmacodynamic profiles even in patients with renal and hepatic damage. Hence, this review purports to outline CFZ as a newer beneficial drug for type 2 diabetes mellitus.
维普期刊数据库